Tuberculosis (TB)

US, 26 countries launch effort to fight outbreaks

The U.S. and 26 other countries began a new effort Thursday to prevent and fight outbreaks of dangerous infectious diseases before they spread around the globe.

U.S. health officials called the Global Health Security Agenda a priority because too many countries lack the health infrastructure necessary to spot a new infection rapidly and sound the alarm before it has time to gain a foothold and even spread into other countries.


Poor Nations Seek New Hepatitis C Drug

Now that wealthy nations have a simple pill regimen that can cure hepatitis C, calls are mounting from representatives of poor nations for the same drugs.
In December, the Food and Drug Administration approved sofosbuvir, from Gilead Sciences. Under the brand name Sovaldi in the United States, it is expected to cost $84,000 per treatment. Four other companies are developing similar pills expected to reach the market in the next three years, with similarly high price tags.

Global Collaboration Forms to Advance Japanese TB Vaccine Technology

Japan's National Institute of Biomedical Innovation("NIBIO"), Aerasand Create Vaccine Company, Ltd("CREATE") announce today that they signed a collaboration agreementon December 26, 2013, on the preclinical and clinical development of new mucosal tuberculosis (TB) vaccines based on NIBIO's human parainfluenza type-2 (rhPIV2) vector technology.

The impact of emerging markets on the global vaccine industry

With the WHO’s pre-qualification of a Japanese Encephalitis vaccine from China National Biotec Group (CNBG) in October 2013, China officially joined the global vaccine market.


MSF pioneers opening up access to humanitarian data

Médecins Sans Frontières (MSF) is pioneering an open-access approach within the humanitarian sector in the hope that other medical aid organisations will follow suit.
MSF decided to make the data its clinical and research staff collect freely available online, says a report published in PLOS Medicine last month (10 December). This is the first time a medical humanitarian organisation has fashioned a policy to openly share its data, MSF says.

Meet the emerging world’s vaccine pioneers

Vaccines work wonders. They prevent disease from striking, which is better than treating it after the fact. They are also relatively cheap and easy to deliver. Yet millions of children do not get them. This has always been stunning to me. When we started the Gates Foundation 15 years ago, we assumed that all of the obvious steps were already being taken, and that we would have to go after the expensive or unproven solutions. In fact, delivering basic vaccines is still one of our top priorities.


Humanitarian fears grow amid South Sudan violence

The World Health Organization is warning of a looming risk of disease outbreaks in South Sudan, where violence has displaced more than 190,000 people since mid-December.

WHO said in a statement received Wednesday that there was a shortage of health care workers, with many fleeing their homes for safety in areas hit by violence.


BCG TB vaccine may be more effective than previously thought

The Bacille Calmette Guérin vaccine against tuberculosis may be more effective against the most common form of the disease than previously thought, according to a study recently published in Clinical Infectious Diseases.


IAVI receives $378,000 grant for vaccine development

The International AIDS Vaccine Initiative announced on Monday the receipt of a $378,000 grant from the Robert Wood Johnson Foundation for the development of new vaccines against major diseases, including AIDS, malaria and tuberculosis.


World Vaccine Congress 2014

Hosted by Terrapinn.

From the Terrapinn website:

For 13 years World Vaccine Congress has been the meeting place for vaccine stakeholders to meet and do business, so far welcoming over 5000 leading pharma, biotechs, academia and governmental representatives.